FESOTERODINE FUMARATE - Generic Drug Details

What are the generic sources for fesoterodine fumarate and what is the scope of patent protection?

Fesoterodine fumarate is the generic ingredient in two branded drugs marketed by Accord Hlthcare, Actavis Labs Fl Inc, Alembic, Alkem Labs Ltd, Amneal Pharms Ny, Ani Pharms, Aurobindo Pharma, Chartwell Rx, Dr Reddys, Hetero Labs Ltd V, Zydus Pharms, and Pfizer, and is included in twelve NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are fourteen drug master file entries for fesoterodine fumarate. Twelve suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for FESOTERODINE FUMARATE

US Patents:	3
Tradenames:	2
Applicants:	12
NDAs:	12
Drug Master File Entries:	14
Finished Product Suppliers / Packagers:	12
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	10
Patent Applications:	407
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FESOTERODINE FUMARATE
What excipients (inactive ingredients) are in FESOTERODINE FUMARATE?	FESOTERODINE FUMARATE excipients list
DailyMed Link:	FESOTERODINE FUMARATE at DailyMed

Recent Clinical Trials for FESOTERODINE FUMARATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute on Aging (NIA)	Phase 3
University of North Carolina, Chapel Hill	Phase 3
Mayo Clinic	Phase 4

See all FESOTERODINE FUMARATE clinical trials

Generic filers with tentative approvals for FESOTERODINE FUMARATE

Applicant	Application No.	Strength	Dosage Form
		8MG	TABLET, EXTENDED RELEASE;ORAL
		4MG	TABLET, EXTENDED RELEASE;ORAL
		8MG	TABLET, EXTENDED RELEASE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Anatomical Therapeutic Chemical (ATC) Classes for FESOTERODINE FUMARATE

G04BD	Drugs for urinary frequency and incontinence
G04B	UROLOGICALS
G04	UROLOGICALS
G	Genito-urinary system and sex hormones

Paragraph IV (Patent) Challenges for FESOTERODINE FUMARATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TOVIAZ	Extended-release Tablets	fesoterodine fumarate	4 mg and 8 mg	022030	16	2012-10-31

US Patents and Regulatory Information for FESOTERODINE FUMARATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alkem Labs Ltd	FESOTERODINE FUMARATE	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	204827-001	Dec 10, 2015	AB	RX	No	No
Dr Reddys	FESOTERODINE FUMARATE	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	204975-002	Aug 13, 2019	AB	RX	No	No
Chartwell Rx	FESOTERODINE FUMARATE	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	204983-001	Jan 5, 2023		DISCN	No	No
Hetero Labs Ltd V	FESOTERODINE FUMARATE	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	204792-001	Jan 9, 2024	AB	RX	No	No

Expired US Patents for FESOTERODINE FUMARATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-002	Oct 31, 2008
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-001	Oct 31, 2008
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-002	Oct 31, 2008
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-002	Oct 31, 2008

Market Dynamics and Financial Trajectory for Fesoterodine Fumarate

Last updated: February 19, 2026

Fesoterodine fumarate is a muscarinic receptor antagonist used to treat overactive bladder (OAB). Approved by the U.S. Food and Drug Administration (FDA) in 2008, it is marketed under the brand name Toviaz by Pfizer. The drug's market performance is influenced by competitive landscape, patent status, regulatory factors, and prescribing trends.

Market Overview

Development and Approval Timeline

• Initial approval: April 2008 (FDA) [1].
• Patent expiration: Anticipated around 2025, with some exclusivity rights maintained via patents on specific formulations and uses.
• Market entry: Primarily the United States, with limited availability in Europe, due to regional marketing authorizations.

Key Attributes

• Indications: Overactive bladder, urinary urgency, incontinence.
• Mechanism of action: Selective antagonist of M3 muscarinic receptors.
• Dosage: 4 mg once daily, with a potential increase to 8 mg based on efficacy and tolerability.

Competitive Landscape

Primary Competitors

• Oxybutynin: First-generation anticholinergic, lower cost, higher side-effect profile.
• Solifenacin: More selective, marketed as Vesicare.
• Darifenacin: Higher M3 selectivity, marketed as Enablex.
• Tolterodine: Similar efficacy, marketed as Detrol.

Market Share Distribution

Drug	Estimated Market Share (2022)	Key Differentiators
Oxybutynin	35%	Cost-effective, generic
Solifenacin	25%	M3 selectivity, longer half-life
Darifenacin	15%	Fewer anticholinergic side effects
Fesoterodine	10%	Once-daily dosing, favorable tolerability
Others	15%	Includes newer agents

Market Penetration Challenges

• Competition from generics for older drugs like oxybutynin.
• Prescribing inertia favoring established medications.
• Side-effect concerns, especially dry mouth and constipation.

Regulatory and Patent Landscape

Patent Status

• Patent protections have expired or are set to expire by 2025.
• Pfizer holds formulation and use patents until 2024–2025, subject to legal challenges and patent extensions.

Regulatory Trends

• Post-approval, no new market approvals for fesoterodine outside the U.S.
• Limited generic development in the U.S., as patent litigation persists.
• European markets have approved similar drugs but with different patent protections.

Revenue and Financial Trajectory

Historical Sales Data

Year	U.S. Sales (USD millions)	Global Sales (USD millions)
2008	150	250
2015	250	400
2020	200	350
2022	180	330

Note: Sales peaked around 2015, then declined mildly due to patent expirations and market competition.

Future Projections

• As patent protections approach expiration, revenue is expected to decline unless new formulations or indications are developed.
• Market growth forecast from USD 180 million (2022) to approximately USD 150 million by 2025, driven by price erosion and generic competition.
• Potential upside from combination therapies or new delivery modalities.

Market Drivers and Constraints

Drivers

• Increasing prevalence of OAB (estimated 12%–17% globally).
• Growing awareness and diagnosis of urinary disorders.
• Preference for once-daily oral medications with favorable tolerability.

Constraints

• Patent expiration and generic entry reducing prices.
• Competitive development of more selective or novel agents.
• Side effects impacting patient adherence.

Strategic Considerations

For Pharmaceutical Developers

• Focus on extending patent life via new formulations, such as extended-release or combination pills.
• Invest in clinical trials targeting new indications or improved safety profiles.
• Explore niche markets such as treatment in specific populations (e.g., elderly) or regional markets.

For Investors and Competitors

• Monitor patent litigation and exclusivity periods for potential market entry.
• Evaluate pipeline drugs with better safety or efficacy profiles.
• Consider geographic expansion where regulatory barriers are lower.

Key Takeaways

• Fesoterodine fumarate's market is facing revenue decline due to patent expiry and generic competition.
• The drug maintains a niche with favorable tolerability and compliance advantages.
• Future growth depends on pipeline innovation, regulatory extensions, and regional market strategies.

FAQs

1. What factors influence fesoterodine fumarate’s market share? Pricing, patent protection, clinical efficacy, side-effect profile, and patient adherence.

2. When will fesoterodine’s patent protections expire? Most recent patents expire around 2024–2025, opening opportunities for generic competition.

3. What are the primary competitors to fesoterodine? Solifenacin, darifenacin, oxybutynin, and tolterodine.

4. Can fesoterodine be prescribed outside the U.S.? Yes, but approval and market availability vary by country, influenced by regional regulatory decisions.

5. What strategies could extend the drug’s market life? Development of new formulations, expanding indications, and regional market penetration.

---

References

[1] U.S. Food and Drug Administration. (2008). FDA approves Toviaz for overactive bladder. Retrieved from https://www.fda.gov/